NIBRT Wins Best Supplier Award at 2025 Invest in Ireland Awards

The NIBRT team is proud to announce that we have been awarded the Best Supplier accolade at the 2025 Invest in Ireland Awards. This event celebrates excellence in Irish foreign direct investment (FDI), recognising the contributions of organisations that drive growth, innovation and talent development across key industries.

Recognising Excellence in Biopharma Investment Support

The judging panel highlighted NIBRT’s key role in fostering biopharma investment in Ireland, specifically through:

  • Training and Education: Each year, NIBRT provides training and education to over 5,000 individuals, equipping them with the skills needed for success in the biopharma manufacturing sector.

  • Research: Our partnerships with leading biopharma companies enable cutting-edge scientific research, advancing technological innovation and enhancing industry capabilities.

A Special Acknowledgement for Our Partnership with Eli Lilly

In addition to the Best Supplier Award, we were delighted to see our partnership with Eli Lilly recognised in the Staff Uplifting Award category. This collaboration has been instrumental in training and developing Lilly’s manufacturing teams as they prepare for operations at their new Limerick manufacturing facility.

Set to be one of Lilly’s most advanced sites to date, the Limerick facility is designed as a fully integrated digital site, leveraging the latest in machine automation, manufacturing execution systems, and data technologies. We are proud to have played a role in ensuring that Lilly’s workforce is equipped with the expertise to excel in this state-of-the-art environment.

Driving Ireland’s Biopharma Industry Forward

At NIBRT, we remain committed to supporting the continued growth of the biopharma industry in Ireland. We extend our thanks to Invest in Ireland for this recognition and to our partners, clients and team members who make achievements like this possible. We look forward to continuing our journey of innovation and excellence in biopharma training and research.